Research Library

Large-scale proteomics studies are being increasingly applied to detect and characterize differential protein expression patterns in health and disease. Proteomics has the potential to provide crucial insights for biomarker discovery and drug development.

In fact, proteins are the primary target of nearly all drugs currently in development. However, conventional proteomics assays are constrained by a lack of sensitivity, particularly for low abundance proteins, and the inability to detect proteins over a wide range of concentrations. Sensitivity is key for analyzing plasma and serum samples in which only 22 proteins make up approximately 99 percent of the total protein mass, with protein concentrations spanning over 10 orders of magnitude.

This technical note from Olink outlines a protocol to detect thousands of proteins representing major biological pathways simultaneously with high sensitivity and specificity using Olink Explore, a high-throughput protein biomarker discovery platform based on Olink’s Proximity Extension Assay (PEA) technology coupled with NGS readout.

Offered Free by: Olink
See All Resources from: Olink